[go: up one dir, main page]

WO2018190365A1 - Marqueur de douleur neuropathique et son utilisation - Google Patents

Marqueur de douleur neuropathique et son utilisation Download PDF

Info

Publication number
WO2018190365A1
WO2018190365A1 PCT/JP2018/015200 JP2018015200W WO2018190365A1 WO 2018190365 A1 WO2018190365 A1 WO 2018190365A1 JP 2018015200 W JP2018015200 W JP 2018015200W WO 2018190365 A1 WO2018190365 A1 WO 2018190365A1
Authority
WO
WIPO (PCT)
Prior art keywords
dorsal root
root ganglion
antibody
patient
detecting
Prior art date
Application number
PCT/JP2018/015200
Other languages
English (en)
Japanese (ja)
Inventor
潤一 吉良
敬之 藤井
今日子 飯沼
山▲崎▼　亮
大介 土本
雄作 中別府
Original Assignee
国立大学法人九州大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 国立大学法人九州大学 filed Critical 国立大学法人九州大学
Priority to JP2019512547A priority Critical patent/JP7067800B2/ja
Publication of WO2018190365A1 publication Critical patent/WO2018190365A1/fr

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor

Definitions

  • the present invention relates to a neuropathic pain marker and use thereof. More specifically, the present invention relates to a neuropathic pain marker, a method for detecting neuropathic pain, and a diagnostic kit for neuropathic pain.
  • This application claims priority based on provisional application No. 62 / 484,406 filed provisionally in the United States on April 12, 2017, the contents of which are incorporated herein by reference.
  • Neuropathic pain is an intractable disease that includes various pathologies defined as “pain caused by lesions and diseases of the somatosensory nervous system” by the International Association for Pain (IASP). It is one of sexual pain (for example, refer nonpatent literature 1).
  • Peripheral nerve fibers are classified into A ⁇ fibers, A ⁇ fibers, A ⁇ fibers, B fibers, and C fibers according to the presence / absence of myelin sheath, diameter, conduction velocity, and the like.
  • nerve fibers having a larger diameter tend to have a higher conduction speed
  • nerve fibers that are myelinated tend to have a higher conduction speed.
  • a ⁇ fibers, A ⁇ fibers, A ⁇ fibers, and B fibers are myelinated fibers
  • C fibers are unmyelinated fibers.
  • a ⁇ fibers which are small-diameter myelinated fibers
  • C fibers which are unmyelinated fibers.
  • the nerve conduction test which is a general test for peripheral neuropathy, examines A ⁇ fibers, which are large-diameter myelinated fibers. For this reason, an abnormality cannot be detected even if a peripheral neuropathy test common to patients with neuropathic pain is performed. As a result, many patients with neuropathic pain are determined to be of unknown cause or psychogenic, and have not yet been diagnosed.
  • an object of the present invention is to provide a technique for detecting neuropathic pain.
  • the present invention includes the following aspects.
  • [1] Use of autoantibodies against small unmyelinated dorsal root ganglion neurons as a neuropathic pain marker.
  • [2] The use according to [1], wherein the autoantibody is an anti-Plexin D1 antibody.
  • [3] A method for detecting neuropathic pain, comprising detecting autoantibodies against small unmyelinated dorsal root ganglion neurons in a blood sample derived from a patient, wherein the autoantibodies are detected.
  • a human or non-human animal-derived dorsal root ganglion tissue or spinal dorsal horn tissue is contacted with a patient-derived blood sample, Detecting human IgG antibodies bound to ganglion tissue or spinal dorsal horn tissue; detecting myelinated dorsal root ganglion neurons or nerve fibers thereof in the dorsal root ganglion tissue or spinal dorsal horn tissue; Wherein the human IgG antibody binds to a neuron other than the myelinated dorsal root ganglion neuron, indicating that an autoantibody against a small unmyelinated dorsal root ganglion neuron has been detected.
  • Detecting a myelinated dorsal root ganglion neuron includes immunostaining the dorsal root ganglion tissue with an anti-S100 ⁇ antibody, and the neuron immunostained with the anti-S100 ⁇ antibody is a myelinated dorsal root nerve
  • a human or non-human animal-derived dorsal root ganglion tissue or spinal cord dorsal horn tissue is contacted with a patient-derived blood sample, Detecting a human IgG antibody bound to the ganglion tissue or the dorsal horn tissue of the spinal cord; detecting unmyelinated dorsal root ganglion neurons or nerve fibers thereof in the dorsal root ganglion tissue or the dorsal horn tissue of the spinal cord; The method according to [3], wherein binding of the human IgG antibody to the unmyelinated dorsal root ganglion neuron indicates that an autoantibody against a small unmyelinated dorsal root ganglion neuron has been detected.
  • Detecting an unmyelinated dorsal root ganglion neuron includes contacting the dorsal root ganglion tissue with isolectin B4, and the neuron to which the isolectin B4 is bound is an unmyelinated dorsal root ganglion neuron.
  • the autoantibody is an anti-Plexin D1 antibody.
  • a method for detecting neuropathic pain comprising contacting a blood sample derived from a patient with a human cell or non-human animal cell expressing Plexin D1, and detecting a human IgG antibody bound to the cell.
  • the amount of the human IgG antibody detected is higher than the amount of the human IgG antibody that binds to the cell.
  • a method of showing that it is suffering from neuropathic pain comprising an anti-human IgG antibody and a detection agent for myelinated dorsal root ganglion neurons or a detection agent for unmyelinated dorsal root ganglion neurons.
  • the diagnostic kit according to [11], wherein the anti-human IgG antibody is an anti-human IgG2 antibody.
  • the diagnostic kit according to [11] or [12], wherein the drug for detecting myelinated dorsal root ganglion neurons is an anti-S100 ⁇ antibody.
  • the diagnostic kit according to any one of [11] to [13], wherein the detection agent for unmyelinated dorsal root ganglion neurons is isolectin B4.
  • a diagnostic kit for neuropathic pain comprising an anti-human IgG antibody and a Plexin D1 protein.
  • the diagnostic kit according to [15], wherein the anti-human IgG antibody is an anti-human IgG2 antibody.
  • the present invention can provide a technique for detecting neuropathic pain.
  • (A) to (f) are fluorescence micrographs showing the results of Experimental Example 2.
  • (A) to (d) are fluorescence micrographs showing the results of Experimental Example 2.
  • (A) to (d) are fluorescence micrographs showing the results of Experimental Example 3.
  • (A) to (c) are fluorescence micrographs showing the results of double staining of patient serum and isolectin B4 in Experimental Example 4.
  • (A) to (c) are fluorescence micrographs showing the results of double staining of patient serum and anti-CGRP antibody in Experimental Example 4.
  • (A)-(c) are fluorescence micrographs showing the results of double staining of patient serum and anti-S100 ⁇ antibody in Experimental Example 4.
  • (A)-(c) are fluorescence micrographs showing the results of double staining of patient serum and anti-TRPV1 antibody in Experimental Example 4.
  • (A) to (c) are fluorescence micrographs showing the results of double staining of patient serum and anti-P2X3 antibody in Experimental Example 4.
  • (A)-(c) are fluorescence micrographs showing the results of double staining of patient serum and anti-CGRP antibody in Experimental Example 5.
  • (A) to (c) are fluorescence micrographs showing the results of double staining of patient serum and isolectin B4 in Experimental Example 5.
  • (A) to (c) are fluorescence micrographs showing the results of double staining of patient serum and anti-PKC ⁇ antibody in Experimental Example 5.
  • (A) is an optical micrograph showing the results of Experimental Example 6.
  • (B) and (c) are fluorescence micrographs showing the results of Experimental Example 6.
  • (A) to (c) are fluorescence micrographs showing the results of double staining of patient serum and anti-TH antibody in Experimental Example 6.
  • (A) to (c) are fluorescence micrographs showing the results of double staining of patient serum and anti-VIP antibody in Experimental Example 6.
  • A) And (c) is a photograph which shows the result of the western blotting in Experimental example 7.
  • FIG. (B) is a photograph showing the results of SDS-PAGE and silver staining in Experimental Example 7.
  • (A) to (c) are fluorescence micrographs showing the results of Experimental Example 8.
  • FIG. (A) is a graph showing the results of quantitative real-time PCR in Experimental Example 9.
  • B is a photograph showing the results of Western blotting in Experimental Example 9.
  • (A) to (c) are fluorescence micrographs showing the results of Experimental Example 9.
  • (A) is an optical micrograph showing the results of Experimental Example 9.
  • (B) and (c) are fluorescence micrographs showing the results of Experimental Example 9.
  • (D) is a merged photograph of (a) to (c).
  • (A) And (b) is the fluorescence micrograph which shows the result of Experimental example 10.
  • FIG. (C) is the graph which digitized the result of (a) and (b).
  • (A) to (f) are fluorescence micrographs showing the results of Experimental Example 11.
  • (A) to (d) are photographs showing the results of Western blotting in Experimental Example 12. It is a photograph which shows the result of the western blotting in Experimental example 13.
  • the present invention provides a neuropathic pain marker.
  • a neuropathic pain marker As will be described later in the Examples, the inventors have revealed that autoantibodies against small unmyelinated dorsal root ganglion neurons are markers of neuropathic pain. Thus, the detection of autoantibodies against small unmyelinated dorsal root ganglion neurons in the patient serum indicates that the patient has neuropathic pain.
  • neuropathic pain can be easily detected by the marker of this embodiment.
  • This embodiment can also be said to provide the use of autoantibodies against small unmyelinated dorsal root ganglion neurons as neuropathic pain markers.
  • it can be said to provide a method of using autoantibodies against small unmyelinated dorsal root ganglion neurons as a neuropathic pain marker.
  • the autoantibody against the small unmyelinated dorsal root ganglion neuron may be an anti-Plexin D1 antibody or an autoantibody against a small unmyelinated dorsal root ganglion neuron other than the anti-Plexin D1 antibody.
  • anti-Plexin D1 antibody is present in the serum of a patient having neuropathic pain.
  • the RefSeqID of the human Plexin D1 protein is NP_055918
  • the RefSeqID of the mouse Plexin D1 protein is NP_080652.
  • the anti-Plexin D1 antibody in a blood sample derived from a patient may be detected by, for example, a lateral flow immunoassay method, an ELISA method, a Western blotting method, or the like.
  • a method of detecting an autoantibody bound to Plexin D1 protein with an anti-human IgG antibody, and the like are mentioned.
  • Plexin D1 is a molecule conventionally known as a neurogenesis guidance factor, a semaphorin receptor involved in immune cell differentiation and activation, and the like. Conventionally, the relationship between Plexin D1 and pain has not been reported.
  • Detection of the presence of anti-Plexin D1 antibody present in the patient's serum or autoantibodies against unidentified small unmyelinated dorsal root ganglion neurons indicates that the patient has neuropathic pain . That is, by detecting an anti-Plexin D1 antibody present in a patient's serum or an autoantibody against an unidentified small unmyelinated dorsal root ganglion neuron, neuropathic pain that has been conventionally diagnosed as unknown is eliminated. Diagnosis is possible.
  • the present embodiment is a data collection method for diagnosing whether or not a patient suffers from neuropathic pain, and is an anti-PlexinD1 antibody present in the patient's serum or an unidentified small antigen. It can also be a method comprising detecting the presence of autoantibodies against dorsal root ganglion neurons.
  • the data collection method does not include a step in which a doctor determines the patient's condition.
  • an anti-small unmyelinated dorsal root ganglion neuron antibody When an anti-small unmyelinated dorsal root ganglion neuron antibody is detected in the patient's serum, it can be diagnosed as small fiber neuropathy. Small fiber neuropathy can be treated with immunotherapy.
  • Plexin D1 autoantibody-positive or antigen-unidentified autoantibody-positive neuropathic pain patients with small unmyelinated dorsal root ganglion neurons can be treated differently from patients with neuropathic pain due to other causes It is.
  • the neuropathic pain in these patients can be treated by immunotherapy such as administration of corticosteroids, administration of immunosuppressants, high-dose immunoglobulin therapy, plasma exchange therapy, and the like.
  • immunotherapy such as administration of corticosteroids, administration of immunosuppressants, high-dose immunoglobulin therapy, plasma exchange therapy, and the like.
  • an analgesic agent such as an SCN9A inhibitor, an SCN10A inhibitor, or a P2X3 receptor antagonist that targets small-diameter unmyelinated fibers.
  • the present invention relates to a method for detecting neuropathic pain, comprising detecting an autoantibody against a small unmyelinated dorsal root ganglion neuron in a blood sample derived from a patient, wherein the autoantibody comprises Detecting provides a method for indicating that the patient is suffering from neuropathic pain.
  • the method of the present embodiment may be referred to as a fluorescent indirect antibody method (IFA).
  • the method of the first embodiment is a data collection method for diagnosing whether or not a patient suffers from neuropathic pain.
  • the data collection method does not include a step in which a doctor determines the patient's condition.
  • detecting autoantibodies against small unmyelinated dorsal root ganglion neurons involves contacting a patient-derived blood sample with dorsal root ganglion tissue or spinal dorsal horn tissue derived from a human or non-human animal. Detecting a human IgG antibody bound to the dorsal root ganglion tissue or the dorsal horn tissue of the spinal cord; and a myelinated dorsal root ganglion neuron or a nerve fiber thereof in the dorsal root ganglion tissue or the dorsal horn tissue of the spinal cord.
  • the human IgG antibody binds to a neuron other than the myelinated dorsal root ganglion neuron, indicating that an autoantibody against a small unmyelinated dorsal root ganglion neuron has been detected. There may be.
  • an autoantibody against a small unmyelinated dorsal root ganglion neuron that has not been identified with an antigen is detected. be able to.
  • the non-human animal is not particularly limited, and examples thereof include mice, rats, hamsters, guinea pigs, rabbits, cats, dogs, monkeys, sheep, pigs, goats, cows, horses and the like.
  • the inventors obtained sera from patients with neuropathic pain, tissue sections of human dorsal root ganglia, tissue sections of human dorsal horn, tissue sections of mouse dorsal root ganglia. It was clarified that autoantibodies against small unmyelinated dorsal root ganglion neurons can be detected by reacting with tissue slices of the dorsal horn of mouse spinal cord and detecting the binding.
  • detecting the myelinated dorsal root ganglion neuron includes immunostaining the dorsal root ganglion tissue with an anti-S100 ⁇ antibody, and the neurons immunostained with the anti-S100 ⁇ antibody It may be determined that it is a neuron. As described later in the Examples, the inventors have revealed that autoantibodies derived from patients with neuropathic pain do not colocalize with anti-S100 ⁇ antibodies.
  • detecting autoantibodies against small unmyelinated dorsal root ganglion neurons involves contacting a patient-derived blood sample with dorsal root ganglion tissue or spinal dorsal horn tissue derived from a human or non-human animal. Detecting a human IgG antibody bound to the dorsal root ganglion tissue or the spinal dorsal horn tissue, and an unmyelinated dorsal root ganglion neuron or a nerve fiber thereof in the dorsal root ganglion tissue or the spinal dorsal horn tissue.
  • the human IgG antibody bound to the unmyelinated dorsal root ganglion neuron may indicate that an autoantibody against a small unmyelinated dorsal root ganglion neuron has been detected. Good.
  • Non-human animals are the same as described above. Further, detecting the unmyelinated dorsal root ganglion neuron includes contacting the dorsal root ganglion tissue with isolectin B4, and determining that the neuron to which the isolectin B4 is bound is an unmyelinated dorsal root ganglion neuron. May be. As described later in the Examples, the inventors revealed that autoantibodies derived from patients with neuropathic pain co-localize with isolectin B4.
  • the autoantibody against small unmyelinated dorsal root ganglion neurons contained in a patient-derived blood sample may be an IgG2 antibody.
  • IgG2 antibody As will be described later in the Examples, the inventors have revealed that the IgG subclass of autoantibodies derived from patients with neuropathic pain is IgG2.
  • the autoantibody against small unmyelinated dorsal root ganglion neurons contained in a patient-derived blood sample may be an anti-Plexin D1 antibody.
  • the inventors have clarified that the autoantibody derived from a patient having neuropathic pain is an anti-Plexin D1 antibody.
  • the present invention is a method for detecting neuropathic pain, wherein a human cell or non-human animal cell expressing Plexin D1 is contacted with a blood sample derived from a patient, and the human IgG antibody bound to the cell The amount of the human IgG antibody detected is greater than the amount of the human IgG antibody that binds to the cell when the blood sample is contacted with a cell that does not express Plexin D1. Provides a method of indicating that the patient is suffering from neuropathic pain.
  • the method of the second embodiment is a data collection method for diagnosing whether or not a patient suffers from neuropathic pain.
  • the data collection method does not include a step in which a doctor determines the patient's condition.
  • the method of the second embodiment is mainly different from the method of the first embodiment in that the antigen of the autoantibody is limited to Plexin D1 protein.
  • Non-human animals are the same as described above.
  • the cell that expresses Plexin D1 may be a cell that originally expresses Plexin D1, or may be a cell that expresses Plexin D1 as a result of introducing a Plexin D1 expression vector.
  • HeLa cells can be used as cells that express Plexin D1.
  • the cell that does not express Plexin D1 may be a cell that originally does not express Plexin D1, may be a cell in which the PLXND1 gene that encodes the Plexin D1 protein is disrupted, or Plexin D1. It may be a cell in which the expression level of is reduced. Specifically, for example, as described later in Examples, HeLa cells into which siRNA for the PLXND1 gene has been introduced can be used as cells that do not express Plexin D1.
  • the autoantibodies contained in the patient-derived blood sample may be IgG2 antibodies.
  • the present invention provides a diagnostic kit for neuropathic pain comprising an anti-human IgG antibody and a detection agent for myelinated dorsal root ganglion neurons or a detection agent for unmyelinated dorsal root ganglion neurons. To do.
  • a patient-derived blood sample may be detected by anti-human IgG antibody after contacting a patient-derived blood sample with dorsal root ganglion tissue or spinal dorsal horn tissue derived from a human or non-human animal.
  • the anti-human IgG antibody may be an anti-human IgG2 antibody.
  • a detection agent for myelinated dorsal root ganglion neurons or a detection agent for unmyelinated dorsal root ganglion neurons caused the patient-derived IgG antibody to bind to myelinated dorsal root ganglion neurons, or unmyelinated dorsal root ganglion neurons.
  • Anti-S100 ⁇ antibody can be used as a detection agent for myelinated dorsal root ganglion neurons.
  • isolectin B4 is mentioned as a detection agent of an unmyelinated dorsal root ganglion neuron.
  • the present invention provides a diagnostic kit for neuropathic pain comprising an anti-human IgG antibody and a Plexin D1 protein.
  • kits of this embodiment it is easily detected whether autoantibodies to Plexin D1 protein are present in a blood sample derived from a patient, for example, by a lateral flow immunoassay method, an ELISA method, a Western blotting method, or the like. be able to.
  • the Plexin D1 protein the full length of the Plexin D1 protein may be used, the extracellular domain of the Plexin D1 protein may be used, or the Plexin D1 protein effective for detecting autoantibodies. An epitope part is specified, and a shorter partial peptide may be used.
  • a recombinant human Plexin D1 protein model “4160-PD”, R & D Systems, the amino acid sequence is shown in SEQ ID NO: 8) described later in Examples can be used.
  • the anti-human IgG antibody may be an anti-human IgG2 antibody.
  • the present invention is a method for diagnosing and treating neuropathic pain in a patient, comprising collecting a blood sample from the patient, and a small unmyelinated dorsal root ganglion neuron in the blood sample. Detecting whether there is an autoantibody against, and diagnosing that the patient is neuropathic pain and having been diagnosed with neuropathic pain when the autoantibody is present.
  • the patient is administered an effective amount of a drug selected from the group consisting of corticosteroids, immunosuppressants, SCN9A inhibitors, SCN10A inhibitors, P2X3 receptor antagonists, or massive immunoglobulin therapy
  • a method is provided comprising performing plasma exchange therapy.
  • Example 1 Collection of blood sample
  • Blood samples were collected from patients with neuropathic pain.
  • the diagnostic criteria for neuropathic pain proposed by the International Pain Society (Finnerup NB, et al., Neuropathic pain: an updated grading system for research and clinical practice., Pain, vol. 157 (8), 1599-1606, 2016.), 110 patients who met the probable and define criteria were included.
  • the breakdown of patients with neuropathic pain is 22 patients with atopic myelitis, 17 patients with optic neuromyelitis (NMOSD), 15 patients with relapsing-remitting multiple sclerosis (RRMS), multiple chronic inflammatory demyelinating 14 patients with neuritis (CIDP), 10 patients with Sjogren's syndrome with spinal root peripheral neuritis, 10 patients with neurosarcoidosis, 6 patients with Churg Strauss, patients with systemic lupus erythematosus (SLE) with myelitis and peripheral neuritis 4 patients, 3 patients with neuro-Behcet's disease (nBD), 2 patients with acromegaly, 2 patients with drug-induced neuropathy, 2 patients with vitamin deficiency neuropathy, 1 patient with neuropathy positive for anti-SGPG antibody, Guillain Valley There were 1 syndrome patient and 1 cryoglobulinemia patient.
  • blood samples were also collected from healthy individuals and patients without neuropathic pain (total of 50 patients).
  • the breakdown of 50 is 20 healthy individuals, 20 patients with neurodegenerative diseases (of which 6 are amyotrophic lateral sclerosis, 4 are multisystem atrophy, and 3 are spinocerebellar degeneration) 2 had Parkinson's disease, 2 had normal pressure hydrocephalus, 1 had Alzheimer's disease, 1 had dementia, and 1 had basal ganglia degeneration. ), 10 patients with collagen vascular disease (of which 4 were systemic lupus erythematosus, 4 were Behcet's disease, and 2 were Sjogren's syndrome).
  • PBS phosphate buffered saline
  • tissue section was immersed in xylene for 5 minutes three times to deparaffinize. Subsequently, immersing the tissue section in 100% ethanol for 5 minutes was repeated twice and hydrated. Subsequently, antigen activation treatment was performed. Specifically, the tissue sections were boiled in citrate buffer (pH 6.0) at 120 ° C. for 10 minutes, slowly cooled at room temperature over 15 minutes, and washed twice with PBS for 5 minutes.
  • citrate buffer pH 6.0
  • a secondary antibody Alexa 488-labeled anti-human IgG antibody, Thermo Fisher Scientific
  • diluted 500-fold was brought into contact with the tissue section and allowed to stand at room temperature for 1 hour to carry out an antigen-antibody reaction. Subsequently, the plate was washed twice with PBS for 5 minutes.
  • FIG. 1 (a) is a representative fluorescence micrograph showing the result of a tissue section of a mouse dorsal root ganglion reacted with a control serum.
  • the scale bar indicates 50 ⁇ m.
  • 1 (b)-(f) show autoantibodies detected in tissue sections of mouse dorsal root ganglia reacted with serum from patients with neuropathic pain (cases 1-5, respectively). It is the fluorescence micrograph which shows the typical result done.
  • the scale bar indicates 50 ⁇ m.
  • FIG. 2 (a) is a representative fluorescence micrograph showing the result of a tissue section of a mouse spinal cord reacted with serum from the same healthy person as in FIG. 1 (a).
  • the scale bar indicates 50 ⁇ m.
  • FIG. 2 (b) is a fluorescence micrograph of the same sample as FIG. 2 (a) taken at high magnification. The scale bar indicates 50 ⁇ m.
  • FIG. 2 (c) is a representative fluorescence micrograph showing the result of a tissue section of a mouse spinal cord reacted with serum from the same patient (case 5) as in FIG. 1 (f).
  • the scale bar indicates 50 ⁇ m.
  • FIG. 2 (d) is a fluorescence micrograph of the same sample as FIG. 2 (c) taken at high magnification.
  • the scale bar indicates 50 ⁇ m.
  • the method of this experimental example may be referred to as a fluorescent indirect antibody method (tissue-based indirect immunofluorescence assay, IFA).
  • Table 2 shows the clinical characteristics of 11 patients who contained autoantibodies reactive to tissue sections of mouse dorsal root ganglia.
  • 3 (a) to 3 (d) are representative fluorescence micrographs showing typical results of detecting autoantibodies of IgG1, IgG2, IgG3, and IgG4, respectively.
  • the scale bar indicates 50 ⁇ m.
  • IgG subclass of autoantibodies was IgG2 in all 11 patient-derived sera.
  • Double staining with isolectin B4 In the primary antibody reaction, in addition to patient serum diluted 60-fold, isolectin B4 (Iselectin GS-IB 4 From Griffinia simplicifolia, Alexa Fluor 594 Conjugate, thermofischer science, a marker of non-peptide C fiber type dorsal root ganglion neurons The fluorescent indirect antibody method was carried out in the same manner as in Experimental Example 2 except that the reaction was carried out after diluting 500 times.
  • FIG. 4 (a) is a representative fluorescence micrograph showing the result of a tissue section of a mouse dorsal root ganglion reacted with serum from a patient with neuropathic pain.
  • FIG. 4 (b) is a representative fluorescence micrograph showing the result of detecting the binding of isolectin B4 (IB4) in the same field of view as FIG. 4 (a).
  • FIG. 4C is a merged photograph of FIGS. 4A and 4B. The scale bar indicates 50 ⁇ m. As a result, it was revealed that patient-derived autoantibodies colocalized with isolectin B4.
  • FIG. 5 (a) is a representative fluorescence micrograph showing the result of a tissue section of a mouse dorsal root ganglion reacted with serum derived from a patient with neuropathic pain.
  • FIG. 5 (b) is a representative fluorescence micrograph showing the result of detecting the binding of anti-CGRP antibody in the same field of view as FIG. 5 (a).
  • FIG. 5C is a merged photograph of FIGS. 5A and 5B. The scale bar indicates 50 ⁇ m. As a result, it was revealed that patient-derived autoantibodies colocalized only partly with CGRP.
  • Double staining with anti-S100 ⁇ antibody >> In the primary antibody reaction, in addition to patient serum diluted 60 times, the myelinated nerve fibers, A ⁇ fiber type dorsal root ganglion neurons and A ⁇ fiber type dorsal root ganglion neurons, and S100 ⁇ which is a marker of satellite glial cells A fluorescent indirect antibody method was performed in the same manner as in Experimental Example 2 except that the antibody (rabbit polyclonal antibody, Abcam) was diluted 500 times and reacted.
  • FIG. 6 (a) is a representative fluorescence micrograph showing the result of a tissue section of a mouse dorsal root ganglion reacted with serum derived from a patient with neuropathic pain.
  • FIG. 6 (b) is a representative fluorescence micrograph showing the result of detecting the binding of anti-S100 ⁇ antibody in the same field of view as FIG. 6 (a).
  • FIG. 6C is a merged photograph of FIGS. 6A and 6B. The scale bar indicates 50 ⁇ m. As a result, it was revealed that patient-derived autoantibodies do not colocalize with S100 ⁇ .
  • FIG. 7 (a) is a representative fluorescence micrograph showing the result of a tissue section of a mouse dorsal root ganglion reacted with serum derived from a patient with neuropathic pain.
  • FIG. 7 (b) is a representative fluorescence micrograph showing the result of detecting the binding of anti-TRPV1 antibody in the same field of view as FIG. 7 (a).
  • FIG. 7C is a merged photograph of FIGS. 7A and 7B. The scale bar indicates 50 ⁇ m. As a result, it was revealed that some of the patient-derived autoantibodies reacted with TRPV1-positive dorsal root ganglion neurons. This result further supports that patient-derived autoantibodies are associated with neuropathic pain.
  • Double staining with anti-P2X3 antibody In the primary antibody reaction, in addition to patient serum diluted 60 times, antibody (rabbit polyclonal antibody, Abcam) against P2X purinoceptor 3 (P2X3), which is known to be involved in pain perception, was diluted 500 times and reacted.
  • the fluorescent indirect antibody method was performed in the same manner as in Experimental Example 2 except for the points described above.
  • FIG. 8 (a) is a representative fluorescence micrograph showing the result of a tissue section of a mouse dorsal root ganglion reacted with serum derived from a patient with neuropathic pain.
  • FIG. 8 (b) is a representative fluorescence micrograph showing the result of detecting the binding of anti-P2X3 antibody in the same field of view as FIG. 8 (a).
  • FIG. 8C is a merged photograph of FIGS. 8A and 8B. The scale bar indicates 50 ⁇ m. As a result, it was revealed that patient-derived autoantibodies mainly reacted with P2X3-positive dorsal root ganglion neurons. This result further supports that patient-derived autoantibodies are associated with neuropathic pain.
  • FIG. 9 (a) is a representative fluorescence micrograph showing the result of a tissue section of the mouse dorsal spinal cord reacted with serum from a patient with neuropathic pain.
  • FIG. 4B is a representative fluorescence micrograph showing the result of detecting the binding of the anti-CGRP antibody in the same field of view as FIG.
  • FIG. 4C is a merged photograph of FIGS. 4A and 4B.
  • the scale bar indicates 50 ⁇ m.
  • Double staining with isolectin B4 In the primary antibody reaction, in addition to patient serum diluted 60-fold, isolectin B4 (Iselectin GS-IB 4 From Griffinia simplicifolia, Alexa Fluor 594 Conjugate, thermofischer science, a marker of non-peptide C fiber type dorsal root ganglion neurons The fluorescent indirect antibody method was carried out in the same manner as in Experimental Example 2 except that the reaction was carried out after diluting 500 times.
  • FIG. 10 (a) is a representative fluorescence micrograph showing the result of a tissue section of a mouse dorsal spinal cord reacted with serum from a patient having neuropathic pain.
  • FIG. 10 (b) is a representative fluorescence micrograph showing the result of detecting the binding of isolectin B4 in the same field of view as FIG. 10 (a).
  • FIG. 10C is a merged photograph of FIGS. 10A and 10B. The scale bar indicates 50 ⁇ m. As a result, it was revealed that many of the autoantibodies derived from patients reacted with isolectin B4 staining axon terminals located in the spinal cord dorsal horn IIi layer.
  • FIG. 11 (a) is a representative fluorescence micrograph showing the result of a tissue section of the mouse dorsal spinal cord reacted with serum from a patient with neuropathic pain.
  • FIG. 11 (b) is a representative fluorescence micrograph showing the result of detecting the binding of anti-PKC ⁇ antibody in the same field of view as FIG. 11 (a).
  • FIG. 11C is a merged photograph of FIGS. 11A and 11B. The scale bar indicates 50 ⁇ m.
  • the autonomic nerve C fiber is present in the dermis (inner layer of the skin) and shows a distribution pattern similar to protein gene product 9.5 (PGP 9.5), which is a general nerve fiber marker.
  • PGP 9.5 protein gene product 9.5
  • FIG. 12 (a) is an optical micrograph showing the result of hematoxylin-eosin staining of a tissue section of the skin of the hind foot sole of a mouse.
  • the scale bar indicates 50 ⁇ m.
  • “dermis” indicates the dermis and “epidermis” indicates the epidermis.
  • FIG. 12 (b) is a representative fluorescence micrograph showing the result of immunostaining of the control serum.
  • the fluorescent indirect antibody method similar to Experimental Example 2 except that the anti-PGP9.5 antibody (rabbit polyclonal antibody, Abcam) was diluted 500-fold in addition to the control serum diluted 60-fold. Went.
  • nuclei were stained with 4 ', 6-diamidino-2-phenylindole (DAPI).
  • DAPI 6-diamidino-2-phenylindole
  • the scale bar indicates 50 ⁇ m.
  • An enlarged photograph of the arrow is shown in the lower left frame. As a result, the control serum was not reactive with mouse skin.
  • FIG. 12 (c) is a representative fluorescence micrograph showing the results of immunostaining of patient-derived autoantibodies.
  • the fluorescent indirect antibody method similar to Experimental Example 2 except that the anti-PGP9.5 antibody (rabbit polyclonal antibody, Abcam) was diluted 500-fold in addition to the patient serum diluted 60-fold. Went. Also, nuclei were stained with DAPI. The scale bar indicates 50 ⁇ m. An enlarged photograph of the arrow is shown in the lower left frame. As a result, it was revealed that patient-derived autoantibodies bound to the epidermis and PGP9.5 positive skin nerve fibers.
  • ⁇ Double staining with anti-TH antibody Subsequently, in order to identify the autonomic nerve fiber to which the autoantibody derived from the patient binds to the tissue section of the skin of the hind foot sole of the mouse, the antibody against tyrosine hydroxylase (TH), which is a sympathetic nerve marker, is used. Double staining was performed.
  • TH tyrosine hydroxylase
  • the fluorescent indirect antibody method was performed in the same manner as in Experimental Example 2 except that the anti-TH antibody (rabbit polyclonal antibody, Abcam) was diluted 500 times and reacted in addition to patient serum diluted 60 times. It was. Also, nuclei were stained with DAPI.
  • anti-TH antibody rabbit polyclonal antibody, Abcam
  • FIG. 13 (a) is a representative fluorescence micrograph showing the result of the tissue section of the skin of the hind paw plantar of the mouse reacted with serum derived from a patient with neuropathic pain.
  • FIG. 13 (b) is a representative fluorescence micrograph showing the result of detecting anti-TH antibody binding in the same field of view as FIG. 13 (a).
  • FIG. 13C is a merged photograph of FIGS. 13A and 13B. The scale bar indicates 50 ⁇ m. As a result, it was revealed that patient-derived autoantibodies do not stain TH-positive nerve fibers.
  • Double staining with anti-VIP antibody was performed on a tissue section of the skin of the hind foot sole of the mouse.
  • VIP vasoactive intestinal peptide
  • the fluorescent indirect antibody method similar to Experimental Example 2 was used except that the anti-VIP antibody (rabbit polyclonal antibody, Immunostar) was diluted 500 times and reacted in addition to 60-fold diluted patient serum. went. Also, nuclei were stained with DAPI.
  • the anti-VIP antibody rabbit polyclonal antibody, Immunostar
  • FIG. 14 (a) is a representative fluorescence micrograph showing the result of a tissue section of the skin of the hind paw foot of a mouse reacted with serum derived from a patient with neuropathic pain.
  • FIG. 14 (b) is a representative fluorescence micrograph showing the result of detecting the binding of anti-VIP antibody in the same field of view as FIG. 14 (a).
  • FIG. 14C is a merged photograph of FIGS. 14A and 14B. The scale bar indicates 50 ⁇ m. As a result, it was revealed that patient-derived autoantibodies colocalized with VIP-positive nerve fibers.
  • the mouse dorsal root ganglion-derived protein extract was subjected to Western blotting, and as a result of detection with a patient-derived autoantibody that reacted with tissue sections of the mouse dorsal root ganglion, 10 patients out of 11 patients A band having a common immunoreactivity with the antibody was detected. The molecular weight of the band was about 220 kDa.
  • no band having immunoreactivity was detected.
  • FIG. 15 (a) is a photograph showing the result of Western blotting.
  • IFA positive indicates that the result of the fluorescent indirect antibody method is positive
  • IFA negative indicates that the result of the fluorescent indirect antibody method is negative
  • NeP Pt.1 2, 5, 6, 9, 11 "represent patients 1, 2, 5, 6, 9, 11 with neuropathic pain, respectively
  • HC represents a healthy person.
  • the band enclosed with the line is a band detected in common by 10 patient-derived autoantibodies out of 11 patients.
  • mouse dorsal root ganglion-derived protein extract diluted to 1 mg / mL and 0.1 mg of FG beads-Protein G beads (Tamakawa Seiki) were incubated at 4 ° C. for 15 minutes. Subsequently, magnetic separation was performed to remove non-specific protein G adsorbate in the protein extract and crude purification was performed.
  • FIG. 15 (b) is a photograph showing the results of SDS-PAGE and silver staining.
  • lane 1 is a molecular weight marker
  • lane 2 is a mouse dorsal root ganglion-derived protein extract
  • lane 3 is a negative control immunoprecipitation sample
  • lane 4 contains an autoantigen protein. Immunoprecipitation sample.
  • the arrow indicates a band of autoantigen protein slightly larger than 220 kDa.
  • FIG. 15 (c) is a photograph showing the result of subjecting the same sample as in FIG. 15 (b) to Western blotting and detecting with a patient-derived autoantibody.
  • lane 1 is a molecular weight marker
  • lane 2 is a mouse dorsal root ganglion-derived protein extract
  • lane 3 is a negative control immunoprecipitation sample
  • lane 4 contains an autoantigen protein. Immunoprecipitation sample.
  • the arrow indicates a band of autoantigen protein slightly larger than 220 kDa.
  • Plexin D1 has a theoretical molecular weight of approximately 212 kDa. This almost coincided with the molecular weight of the band detected by Western blotting. Plexin D1 is one of the largest molecular weight glycoproteins in nerve tissue. However, the expression of Plexin D1 in human dorsal root ganglia and spinal cord has not been reported.
  • Example 8 (Examination of Plexin D1 expression in human dorsal root ganglia and spinal cord tissue sections) Tissue sections of human lumbar dorsal root ganglia and spinal cord from dead donors were prepared. Subsequently, each tissue section was immunostained and observed with a fluorescence microscope (model “BZ-X700”, Keyence Corporation).
  • FIG. 16 (a) is a fluorescence micrograph showing the result of staining a tissue section of a human dorsal root ganglion with an anti-human Plexin D1 antibody (goat polyclonal antibody, R & D Systems).
  • FIG. 16B shows a neurofilament heavy chain (marker of A ⁇ fiber-type dorsal root ganglion neurons and A ⁇ fiber-type dorsal root ganglion neurons, which are myelinated fibers, in the same field of view as FIG. 16A.
  • the results of staining with an antibody against NFH anti-human phosphorylated NFH antibody, model “SMI31”, mouse monoclonal antibody, Covance; and anti-human non-phosphorylated NFH antibody, model “SMI32”, mouse monoclonal antibody, Covance
  • NFH anti-human phosphorylated NFH antibody
  • model “SMI32” mouse monoclonal antibody, Covance
  • FIG. 16 (c) is a merged photograph of FIG. 16 (a) and FIG. 16 (b).
  • the scale bar indicates 50 ⁇ m.
  • FIG. 16 (d) is a fluorescence micrograph showing the result of staining a tissue section of human spinal cord with anti-human Plexin D1 antibody (goat polyclonal antibody, R & D Systems).
  • FIG. 16 (e) shows an anti-human NFH antibody (anti-human phosphorylated NFH antibody, model “SMI31”, mouse monoclonal antibody, Covance; and anti-human non-phosphorylated NFH antibody in the same field of view as FIG. 16 (d). , Model “SMI32”, mouse monoclonal antibody, Covance)). Also, nuclei were stained with DAPI.
  • FIG. 16 (f) is a merge of the photos of FIG. 16 (d) and FIG. 16 (e).
  • the scale bar indicates 100 ⁇ m.
  • Plexin D1 does not co-localize with NFH-positive myelinated dorsal root ganglion neurons.
  • NFH is mainly present in the dorsal column (PC) and the dorsal horn deep layer (DDH; spinal dorsal horn III to V layers), and more in the dorsal horn superficial layer (SDH). There were few.
  • Plexin D1 is present in the unmyelinated dorsal root ganglion neurons and their axon terminals located in the dorsal horn superficial layer, and this localization pattern is the binding pattern of patient-derived autoantibodies. It was similar.
  • mRNA of the KIF11 gene was amplified as a positive control.
  • GAPDH gene mRNA was amplified as a reference gene.
  • FESI Fast SYBR Green Master Mix
  • PCR was performed with a StepOnePlus real-time PCR system (Thermo Fisher Scientific).
  • PLXND1-specific primers As PLXND1-specific primers, PLXND1 Fwd (5′-AATGGGCGGAACATCGTCAAG-3 ′, SEQ ID NO: 2) and PLXND1 Rev (5′-CGAGACTGGTTGGAAACACAG-3 ′, SEQ ID NO: 3) were used. Further, KIF11 Fwd (5′-TGTTTGATGATCCCCGTAACAAG-3 ′, SEQ ID NO: 4) and KIF11 Rev (5′-CTGAGTGGGAACGACTAGAGT-3 ′, SEQ ID NO: 5) were used as KIF11 specific primers.
  • GAPDH Fwd (5′-ACCCACTCCTCCACCTTTGAC-3 ′, SEQ ID NO: 6) and GAPDH Rev (5′-TGTTGCTGTAGCCAAATTCGTT-3 ′, SEQ ID NO: 7) were used as GAPDH specific primers.
  • FIG. 17 (a) is a graph showing the results of quantitative real-time PCR.
  • “Scrambled siRNA” indicates the result of introducing the control siRNA
  • “PLXND1 siRNA” indicates the result of introducing the siRNA for the PLXND1 gene.
  • FIG. 17 (b) is a photograph showing the result of examining the expression of Plexin D1 protein by Western blotting. ⁇ -actin protein was detected as a loading control.
  • “Scramble siRNA” indicates the result of introducing the control siRNA
  • “PLXND1 siRNA” indicates the result of introducing the siRNA for the PLXND1 gene.
  • BioCoat Collagen I culture slide 8 well (Corning) was added with a preparation solution containing 7.5 nM final concentration of siRNA and 0.45 ⁇ L of Lipofectamine RNAiMAX (Invitrogen) per well to cover the whole well surface, 15 Let stand at room temperature for minutes.
  • HeLa cells were seeded at 8 ⁇ 10 3 cells / well, cultured under conditions of 37 ° C. and 5% CO 2 , and reverse transfection was performed. Subsequently, the medium was changed after 48 hours. Subsequently, 96 hours after reverse transfection, the medium was removed, 4% paraformaldehyde / phosphate buffer (Wako Pure Chemical Industries) was added, and the mixture was allowed to stand at room temperature for 10 minutes, and then the cells were washed with ice-cold PBS ( ⁇ ). Washed 3 times.
  • PBS (-) containing 0.1% Tween 20 (Sigma-Aldrich) was added to each well, left at room temperature for 10 minutes to perform membrane permeation treatment, and then washed twice with PBS (-). . Subsequently, PBS (-) containing 1% gelatin was added to each well and allowed to stand at room temperature for 1 hour for blocking.
  • patient-derived serum IgG diluted 1,000-fold in PBS (-) containing 1% bovine serum albumin (BSA), and anti-Plexin D1 antibody diluted 200-fold (goat polyclonal antibody, R & D Systems)
  • a primary antibody reaction solution containing the solution was added, and the mixture was allowed to stand at room temperature for 1 hour to carry out a primary antibody reaction, and then washed three times with PBS ( ⁇ ).
  • a sample prepared by reacting control serum IgG instead of patient-derived serum IgG was also prepared.
  • Alexa Fluor 488-labeled goat anti-human IgG (H + L) antibody (Thermo Fisher Scientific) diluted 1,000 times
  • Alexa Fluor 594-labeled rabbit anti-goat IgG (H + L) antibody (Thermo) diluted 1,000 times.
  • a secondary antibody reaction solution containing Fischer Scientific 0.1 ⁇ g / mL DAPI
  • the mixture was allowed to stand at room temperature for 1 hour under light shielding, followed by a secondary antibody reaction, and then PBS ( ⁇ ) And washed 3 times. Subsequently, it was observed with a fluorescence microscope (model “BZ-X710”, Keyence Corporation).
  • FIG. 18 (a) is a representative fluorescence micrograph showing the result of detection of control IgG bound to HeLa cells into which no siRNA has been introduced.
  • FIG. 18 (b) is a fluorescence micrograph showing the result of detecting the binding of anti-Plexin D1 antibody in the same field of view as FIG. 18 (a).
  • FIG. 18C is a merged photograph of FIGS. 18A and 18B. The scale bar indicates 100 ⁇ m.
  • FIG. 18 (d) is a representative fluorescence micrograph showing the result of detecting patient-derived autoantibodies bound to HeLa cells into which no siRNA has been introduced.
  • FIG. 18 (e) is a fluorescence micrograph showing the result of detecting the binding of anti-Plexin D1 antibody in the same field of view as FIG. 18 (d).
  • FIG. 18F is a merged photograph of FIGS. 18D and 18E. The scale bar indicates 100 ⁇ m.
  • FIG. 19 (a) is a photomicrograph of HeLa cells into which control siRNA has been introduced, observed in a bright field.
  • FIG. 19B is a fluorescence micrograph showing the result of detecting the binding of a patient-derived autoantibody (Case 5) in the same field of view as FIG.
  • FIG. 19 (c) is a fluorescence micrograph showing the result of detecting the binding of anti-Plexin D1 antibody in the same field of view as FIG. 19 (a).
  • FIG. 19D is a merged photograph of FIGS. 19A, 19B, and 19C. The scale bar indicates 25 ⁇ m.
  • FIG. 19 (e) is a photomicrograph of bright field observation of HeLa cells into which siRNA for the PLXND1 gene has been introduced.
  • FIG. 19 (f) is a fluorescence micrograph showing the result of detecting the binding of the patient-derived autoantibody (Case 5) in the same field of view as FIG. 19 (e).
  • FIG. 19 (g) is a fluorescence micrograph showing the result of detecting the binding of anti-Plexin D1 antibody in the same field of view as FIG. 19 (e).
  • FIG. 19 (h) is a merge of the photos of FIG. 19 (e), FIG. 19 (f) and FIG. 19 (g).
  • the scale bar indicates 25 ⁇ m.
  • FIG. 20 (a) is a representative fluorescence micrograph showing the result of detecting a patient-derived autoantibody (case 5) bound to a HeLa cell into which a control siRNA was introduced.
  • FIG. 20A the nucleus is stained with DAPI.
  • the scale bar indicates 50 ⁇ m.
  • FIG. 20 (b) is a representative fluorescence micrograph showing the result of detecting a patient-derived autoantibody (case 5) bound to a HeLa cell into which siRNA against the PLXND1 gene has been introduced.
  • nuclei are stained with DAPI.
  • the scale bar indicates 50 ⁇ m.
  • FIG. 20 (c) is a graph in which the results of FIGS. 20 (a) and (b) are digitized. As a result, it was revealed that the binding of autoantibodies derived from the patient in case 5 was significantly reduced in HeLa cells into which siRNA for the PLXND1 gene was introduced.
  • FIG. 21 (a) is a fluorescence micrograph showing the result of reacting a patient-derived autoantibody (Case 5) with a tissue section of a mouse dorsal root ganglion.
  • the scale bar indicates 50 ⁇ m.
  • FIG. 21 (b) is a fluorescence micrograph showing the results of reacting a patient-derived autoantibody (Case 5) preincubated with 0.5 ⁇ g / mL Plexin D1 protein to a tissue section of a mouse dorsal root ganglion.
  • the scale bar indicates 50 ⁇ m.
  • FIG. 21 (c) is a fluorescence micrograph showing the result of reacting the patient-derived autoantibody (Case 5) preincubated with 2 ⁇ g / mL Plexin D1 protein to the tissue section of the mouse dorsal root ganglion.
  • the scale bar indicates 50 ⁇ m.
  • FIG. 21 (d) is a fluorescence micrograph showing the result of reacting a patient-derived autoantibody (Case 5) with a tissue section of a mouse spinal cord.
  • the scale bar indicates 50 ⁇ m. Binding of patient-derived autoantibodies was observed at the arrowed portion.
  • FIG. 21 (e) is a fluorescence micrograph showing the result of reaction of a patient-derived autoantibody (Case 5) preincubated with 0.5 ⁇ g / mL Plexin D1 protein to a tissue section of a mouse spinal cord.
  • the scale bar indicates 50 ⁇ m.
  • An arrow is shown at the same position as in FIG.
  • FIG. 21 (f) is a fluorescence micrograph showing the result of reacting a patient-derived autoantibody (case 5) preincubated with 2 ⁇ g / mL Plexin D1 protein to a tissue section of a mouse spinal cord.
  • the scale bar indicates 50 ⁇ m.
  • An arrow is shown at the same position as in FIG.
  • Plexin D1 protein decreased the staining of dorsal root ganglion neurons of patient-derived autoantibodies (Case 5) in a dose-dependent manner of Plexin D1 protein. Similar results were observed with all 11 patient-derived autoantibodies.
  • FIG. 22 (a) is a photograph showing the result of detecting a self-antigen by reacting with a patient-derived autoantibody (case 1).
  • FIG. 22 (b) is a photograph showing a result of detecting autoantigen by reacting a patient-derived autoantibody (case 1) preincubated with 0.5 ⁇ g / mL Plexin D1 protein.
  • FIG. 22 (c) is a photograph showing a result of detecting a self-antigen by reacting with a patient-derived autoantibody (case 2).
  • FIG. 22 (d) is a photograph showing the result of detecting autoantigen by reacting a patient-derived autoantibody (Case 2) preincubated with 0.5 ⁇ g / mL Plexin D1 protein.
  • a protein in which the extracellular domain portion of the PLXND1 gene was expressed (model “4160-PD”, R & D Systems, amino acid sequence is shown in SEQ ID NO: 8) was used.
  • the band size of this protein was predicted to be 165 kDa to 175 kDa.
  • FIG. 23 shows autoantibodies derived from neuropathic pain patients whose results by the fluorescent indirect antibody method were positive (cases 1, 2, 5), and sera derived from neuropathic pain patients whose results by the fluorescent indirect antibody method were negative It is a photograph which shows the result of having detected recombinant human Plexin D1 protein using the serum derived from a healthy person, and a commercially available anti-human Plexin D1 antibody.
  • Plexin D1 is a protein to which an autoantibody derived from a neuropathic pain patient whose result by the fluorescent indirect antibody method is positive.
  • the present invention can provide a technique for detecting neuropathic pain.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention fait appel à un auto-anticorps pour un petit neurone ganglionnaire de racine dorsale non myélinisé en tant que marqueur de douleur neuropathique.
PCT/JP2018/015200 2017-04-12 2018-04-11 Marqueur de douleur neuropathique et son utilisation WO2018190365A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019512547A JP7067800B2 (ja) 2017-04-12 2018-04-11 神経障害性疼痛マーカー及びその使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762484406P 2017-04-12 2017-04-12
US62/484,406 2017-04-12

Publications (1)

Publication Number Publication Date
WO2018190365A1 true WO2018190365A1 (fr) 2018-10-18

Family

ID=63792506

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2018/015200 WO2018190365A1 (fr) 2017-04-12 2018-04-11 Marqueur de douleur neuropathique et son utilisation

Country Status (2)

Country Link
JP (1) JP7067800B2 (fr)
WO (1) WO2018190365A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024162322A1 (fr) * 2023-01-31 2024-08-08 国立大学法人九州大学 Prévention ou traitement d'une douleur neuropathique
CN118962156A (zh) * 2024-09-19 2024-11-15 阿维森纳(广州)健康科技有限公司 一种Plexin-D1抗体检测试剂盒及其在神经系统疼痛疾病中的应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006519983A (ja) * 2003-02-04 2006-08-31 ミレニアム・ファーマシューティカルズ・インコーポレイテッド １６３８６、１５４０２、２１１６５、１４２３、６３６、１２３０３、２１４２５、２７４１０、３８５５４、３８５５５、５５０６３、５７１４５、５９９１４、９４９２１、１６８５２、３３２６０、５８５７３、３０９１１、８５９１３、１４３０３、１６８１６、１７８２７、または３２６２０を使用する、疼痛および疼痛障害を処置する方法および組成物
JP2007518068A (ja) * 2003-11-25 2007-07-05 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ 視神経脊髄炎用マーカー
JP2009506985A (ja) * 2005-07-21 2009-02-19 ステイヒテイング・カソリーケ・ユニベルシタイト 腫瘍の診断及び治療のための標的としてのプレキシンｄ１
JP2013504331A (ja) * 2009-09-14 2013-02-07 バンヤン・バイオマーカーズ・インコーポレーテッド ニューロン損傷診断のためのマイクロｒｎａ、自己抗体およびタンパク質マーカー
JP2013047259A (ja) * 2006-01-10 2013-03-07 Zymogenetics Inc Ｉｌ−３１アンタゴニストを用いて神経組織における疼痛及び炎症を治療する方法
JP2013524220A (ja) * 2010-04-01 2013-06-17 バンヤン・バイオマーカーズ・インコーポレイテッド 神経毒性を検出するためのマーカーおよびアッセイ
EP2816354A1 (fr) * 2013-06-19 2014-12-24 Medizinische Hochschule Hannover Biomarqueur pour la maladie "complex regional pain syndrome" (CRPS)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI100556B (fi) * 1995-03-01 1997-12-31 Biohit Oyj Menetelmä anti-DNA-vasta-aineiden toteamiseksi, diagnostinen menetelmä , reagenssipakkaus ja lääkeaine autoimmuunisairauksia varten
US10620201B2 (en) 2014-01-20 2020-04-14 Pad 4 Di Maria Adele Silvia Denegri S.A.S. In vitro method for predicting, diagnosing and monitoring in therapeutic follow up lupus nephritis

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006519983A (ja) * 2003-02-04 2006-08-31 ミレニアム・ファーマシューティカルズ・インコーポレイテッド １６３８６、１５４０２、２１１６５、１４２３、６３６、１２３０３、２１４２５、２７４１０、３８５５４、３８５５５、５５０６３、５７１４５、５９９１４、９４９２１、１６８５２、３３２６０、５８５７３、３０９１１、８５９１３、１４３０３、１６８１６、１７８２７、または３２６２０を使用する、疼痛および疼痛障害を処置する方法および組成物
JP2007518068A (ja) * 2003-11-25 2007-07-05 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ 視神経脊髄炎用マーカー
JP2009506985A (ja) * 2005-07-21 2009-02-19 ステイヒテイング・カソリーケ・ユニベルシタイト 腫瘍の診断及び治療のための標的としてのプレキシンｄ１
JP2013047259A (ja) * 2006-01-10 2013-03-07 Zymogenetics Inc Ｉｌ−３１アンタゴニストを用いて神経組織における疼痛及び炎症を治療する方法
JP2013504331A (ja) * 2009-09-14 2013-02-07 バンヤン・バイオマーカーズ・インコーポレーテッド ニューロン損傷診断のためのマイクロｒｎａ、自己抗体およびタンパク質マーカー
JP2013524220A (ja) * 2010-04-01 2013-06-17 バンヤン・バイオマーカーズ・インコーポレイテッド 神経毒性を検出するためのマーカーおよびアッセイ
EP2816354A1 (fr) * 2013-06-19 2014-12-24 Medizinische Hochschule Hannover Biomarqueur pour la maladie "complex regional pain syndrome" (CRPS)

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Plexin D1", PERIPHERAL NERVE, vol. 28, no. 2, 1 December 2017 (2017-12-01), pages 279 *
CHOI, Y ET AL.: "Dynamic control of beta-1 integrin adhesion by the plexinD1-sema3E axis", PNAS, vol. 111, no. 1, 7 January 2014 (2014-01-07), pages 379 - 384, XP055559263, Retrieved from the Internet <URL:doi:10.1073/pnas.1314209111> *
FUJII, T ET AL.: "Anti-plexin D1 autoantibody-associated neuropathic pain syndrome is responsive to immunotherapies", JOURNAL OF THE NEUROLOGICAL SCIENCES, vol. 381 supp, 15 October 2017 (2017-10-15), pages 78 - 79, XP085297341, Retrieved from the Internet <URL:https://doi.org/10.1016/j.jns.2017.08.269> *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024162322A1 (fr) * 2023-01-31 2024-08-08 国立大学法人九州大学 Prévention ou traitement d'une douleur neuropathique
CN118962156A (zh) * 2024-09-19 2024-11-15 阿维森纳(广州)健康科技有限公司 一种Plexin-D1抗体检测试剂盒及其在神经系统疼痛疾病中的应用

Also Published As

Publication number Publication date
JP7067800B2 (ja) 2022-05-16
JPWO2018190365A1 (ja) 2020-05-14

Similar Documents

Publication Publication Date Title
Tajik et al. Targeting zonulin and intestinal epithelial barrier function to prevent onset of arthritis
Vincent et al. Autoimmune channelopathies and related neurological disorders
Huang et al. A therapeutic vaccine approach to stimulate axon regeneration in the adult mammalian spinal cord
Sailer et al. Immunolocalization of BK channels in hippocampal pyramidal neurons
Wunsch et al. The enteric nervous system is a potential autoimmune target in multiple sclerosis
Arevalo-Martin et al. Elevated autoantibodies in subacute human spinal cord injury are naturally occurring antibodies
EP2483417B1 (fr) Méthodes de diagnostic et de traitement d&#39;encéphalite ou d&#39;épilepsie
Ding et al. Anti-NMDAR encephalitis induced in mice by active immunization with a peptide from the amino-terminal domain of the GluN1 subunit
Margutti et al. Autoantibodies to the C-terminal subunit of RLIP76 induce oxidative stress and endothelial cell apoptosis in immune-mediated vascular diseases and atherosclerosis
US8354236B2 (en) Detection of neurodegenerative disease
Ren et al. Cross-immunoreactivity between bacterial aquaporin-Z and human aquaporin-4: potential relevance to neuromyelitis optica
DE102018004759A1 (de) Diagnose einer Neuroautoimmunkrankheit
Loewen et al. Genetic and pharmacological manipulation of glial glutamate transporters does not alter infection-induced seizure activity
Danesh-Seta et al. Bee venom–derived BBB shuttle and its correlation with oligodendrocyte proliferation markers in mice model of multiple sclerosis
JPWO2014003008A1 (ja) ヒト汗中に含まれる新規ヒスタミン遊離物質
WO2018190365A1 (fr) Marqueur de douleur neuropathique et son utilisation
US11061027B2 (en) Materials and methods for evaluating and treating cancer
Wang et al. SPK1-transfected UCMSC has better therapeutic activity than UCMSC in the treatment of experimental autoimmune encephalomyelitis model of Multiple sclerosis
Schmieder et al. The CD 20 homolog M s4a8a integrates pro‐and anti‐inflammatory signals in novel M 2‐like macrophages and is expressed in parasite infection
JP6754751B2 (ja) 膜ｓｔｉｍ１を用いた化合物のスクリーニング方法
Bedolla et al. Microglia-derived TGF-β1 ligand maintains microglia homeostasis via autocrine mechanism and is critical for normal cognitive function in adult mouse brain
WO2019202767A1 (fr) Agent antifibrotique et biomarqueur de fibrose
Li et al. Upregulation of spinal MDGA1 in rats after nerve injury alters interactions between neuroligin-2 and postsynaptic scaffolding proteins and increases GluR1 subunit surface delivery in the spinal cord dorsal horn
EP3644061A1 (fr) Diagnostic des maladies auto-immunes bulleuses
Larsson et al. Distribution of transmembrane AMPA receptor regulatory protein (TARP) isoforms in the rat spinal cord

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18784145

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2019512547

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18784145

Country of ref document: EP

Kind code of ref document: A1